F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)



Status:Enrolling by invitation
Conditions:Alzheimer Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:45 - Any
Updated:1/26/2019
Start Date:March 2015
End Date:September 2020

Use our guide to learn which trials are right for you!

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction Due to Alzheimer Disease

This project will collect quantitative pilot data that will allow the characterization of
uptake and binding of 18F-AV-1451 (also known as F 18 T807), a novel tau imaging compound, in
individuals with Progressive Posterior Cortical Dysfunction (PPCD) and logopenic variant
primary progressive aphasia (lvPPA). The primary goal is to develop tau imaging technique as
an antecedent biomarker of cognitive decline. The investigators propose to obtain preliminary
data that will support the possibility of detecting cognitive decline in its earliest stages,
before the occurrence of dementia.


Inclusion Criteria:

1. Male or female participants, at least 45 years of age.

2. Clinical diagnosis of PPCD.

3. Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer
injection, LP; for those unable to undergo an MRI, CT will be used to generate
regions-of-interest).

4. Pre-menopausal women will have a negative urine pregnancy test within 24 hours of T807
drug administration.

Exclusion Criteria:

1. Has any condition that, in the Investigator's opinion, could increase risk to the
participant, limit the participant's ability to tolerate the experimental procedures,
or interfere with the collection/analysis of the data (for example, participants with
severe chronic back pain might not be able to lie still during the scanning
procedures).

2. Is deemed likely unable to perform the imaging procedures for any reason.

3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT
interval.

4. Has hypersensitivity to F 18 T807 or any of its excipients.

5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to
lie still for long periods) that make it unsafe for the individual to participate.

6. Severe claustrophobia.

7. Currently pregnant or breast-feeding.

8. For those electing to undergo the optional lumbar puncture: on anticoagulant of any
form prior to lumbar puncture.
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Phone: 314-362-6737
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials